Now Available: Spotlight on Attovia CEO Tao Fu. Click here to read.
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, announced completion of its $60.75M Series A financing round.
“Fluent’s technology eliminates the need for complex, expensive instrumentation and microfluidic consumables,” said Wouter Meuleman, Partner at Illumina Ventures. “PIPseq is a simple, scalable workflow that can enable single cell sequencing in every lab for many applications while reducing costs and increasing accessibility.”
"This idea that we could infuse these long-lasting, therapeutic protein factories into patients captured our imagination,” said Alexis Ji, Venture Partner at Illumina Ventures. “Rather than patients going to the clinic over and over, the treatment is always there. This creates the potential to offer functional cures for serious diseases.”
Illumina Ventures announced the addition of four new members to its European team. Arnaud Autret, PhD, MSc, will be Principal and Head of European Operations, William Byrne, PhD, be an Associate – Europe, and Ronan Byrne and Ivan Coulter, PhD, BSc, will serve as Venture Advisors – Europe.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
